Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma

NCT02396316 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02396316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02396316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
April 2, 2015
Completion date
September 6, 2016
Enrollment
54 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma, neovascular